GH Research Ireland has closed a $125 million Series B financing round to fund development of its GH001 inhaled 5-MeO-DMT, the company announced. 5-MeO-DMT is psychedelic found in the venom of certain toads. GH is currently developing GH001 for the treatment of treatment resistant depression, and according to the announcement, “The company’s goal is to administer GH001 in a single-day individualized dosing regimen that enables patients to achieve a rapid and durable remission with convenient administration.”
A Phase 1/2 trial of GH001 in patients with treatment resistant depression is ongoing, and GH said that it plans to develop GH001 for additional indications. The company is also developing an injectable formulation of 5-MeO-DMT.
Read the GH Research press release.
